

Supplementary Table S2. Clinical success, failure, and microbiologic eradication - analysis population overall by country

	Australia n=59	Austria n=12	Germany n=29	Italy n=57	Mexico n=59	Spain n=313	UK n=88	Total N=617
Index infection considered as a clinical success by the investigator								
No, n (%)	16 (27.1)	1 (8.3)	8 (27.6)	13 (22.8)	10 (16.9)	75 (24.0)	23 (26.1)	146 (23.7)
95% CI	16.4%, 40.3%	0.2%, 38.5%	12.7%, 47.2%	12.7%, 35.8%	8.4%, 29.0%	19.3%, 29.1%	17.3%, 36.6%	20.4%, 27.2%
Yes, n (%)	36 (61.0)	7 (58.3)	13 (44.8)	34 (59.6)	47 (79.7)	221 (70.6)	57 (64.8)	415 (67.3)
95% CI	47.4%, 73.5%	27.7%, 84.8%	26.4%, 64.3%	45.8%, 72.4%	67.2%, 89.0%	65.2%, 75.6%	53.9%, 74.7%	63.4%, 71.0%
Unknown, n (%)	7 (11.9)	4 (33.3)	8 (27.6)	10 (17.5)	2 (3.4)	17 (5.4)	8 (9.1)	56 (9.1)
95% CI	4.9%, 22.9%	9.9%, 65.1%	12.7%, 47.2%	8.7%, 29.9%	0.4%, 11.7%	3.2%, 8.6%	4.0%, 17.1%	6.9%, 11.6%
If yes*, n (%):								
Missing	0	0	0	0	0	0	0	0
No additional GN antibacterial therapy required for a minimum of 48H targeted to index infection after a minimum of 48H of C/T not including discharge antibiotics or de-escalation	28 (77.8)	5 (71.4)	6 (46.2)	24 (70.6)	31 (66.0)	129 (58.4)	49 (86.0)	272 (65.5)
No death attributed to GN infection	28 (77.8)	6 (85.7)	9 (69.2)	25 (73.5)	10 (21.3)	116 (52.5)	49 (86.0)	243 (58.6)
No further inpatient antibiotic treatment for exacerbation of respiratory infection ≤28 days of stopping C/T	14 (38.9)	5 (71.4)	1 (7.7)	5 (14.7)	11 (23.4)	82 (37.1)	34 (59.6)	152 (36.6)
Resolution of exacerbation of chronic respiratory infection	6 (16.7)	1 (14.3)	0	2 (5.9)	2 (4.3)	46 (20.8)	34 (59.6)	91 (21.9)
Discharge from hospital, ICU, or step-down unit signifying clinical stability	33 (91.7)	7 (100)	6 (46.2)	22 (64.7)	30 (63.8)	172 (77.8)	54 (94.7)	324 (78.1)
No need for re-operation for source control	14 (38.9)	4 (57.1)	2 (15.4)	12 (35.3)	4 (8.5)	49 (22.2)	12 (21.1)	97 (23.4)
Documented microbiological eradication	9 (25.0)	3 (42.9)	2 (15.4)	10 (29.4)	11 (23.4)	74 (33.5)	7 (12.3)	116 (28.0)
Documented microbiological eradication (as reported by investigator), n (%)								
No	43 (72.9)	5 (41.7)	19 (65.5)	37 (64.9)	46 (78.0)	222 (70.9)	73 (83.0)	445 (72.1)
Yes	9 (15.3)	3 (25.0)	2 (6.9)	10 (17.5)	11 (18.6)	74 (23.6)	7 (8.0)	116 (18.8)
Unknown	7 (11.9)	4 (33.3)	8 (27.6)	10 (17.5)	2 (3.4)	17 (5.4)	8 (9.1)	56 (9.1)

*More than one criterion may apply for one patient.

C/T, ceftolozane/tazobactam; GN, gram negative; ICU, intensive care unit; UK, United Kingdom.